A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Summary: Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavan...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clement, Thomas R. Jeffry Evans, Heinz Läubli, Patrick Roth, Rebecca Kristeleit, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Benjamin Wunderlich, Kirk Beebe, Joel Robert Eisner, Heidi Lane, Marc Engelhardt, Thomas Kaindl, Peter Hau, Thomas Hundsberger, Joachim Steinbach
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-06-01
coleção:	Cell Reports Medicine
Assuntos:	lisavanbulin glioma glioblastoma astrocytoma
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666379125002381
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!